According to Heraeus, the deal does not include Umicore’s platinum API business or production facility in South America and other, non-platinum molecules.

“Our mission is to reliably provide customers with the highest quality products – ensuring effective treatment for as many cancer patients as possible,” said Andrea Lamberti, head of Pharmaceutical Ingredients at Heraeus Precious Metals. “This is not just a business opportunity; it's a commitment to excellence and care. By merging our strengths, we create synergies that allow us to offer a robust portfolio at competitive prices, all while maintaining our uncompromising standards of quality.”

Michael Schwarz, commercial director of Umicore’s global API business, added: “Heraeus Precious Metals is the ideal partner for our customers outside of South America as they share our commitment to excellent quality, in a transaction that provides synergies for all parties.”

In 2021, Heraeus Precious Metals already expanded its platinum API production in Hanau, Germany, with a multi-million-euro investment. The increased capacity will further enable the company to respond promptly to high market demand in the future, the company said.